BASEL, Switzerland - The drugmaker Novartis AG said Monday that the European Commission had approved its Exelon skin patch to treat Alzheimer's disease.
The patch, which was approved in the United States by the Food and Drug Administration last July, provides a regular and continuous dose of the drug, which is also called rivastigmine and can be administered in capsule form.
The drug aims to treat the symptoms of mild to moderate dementia by …
Комментариев нет:
Отправить комментарий